<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <!-- Favicon -->
    <link rel="icon" href="https://beleodaq.com/hcp/wp-content/uploads/2019/05/cropped-favicon-Beleodaq-32x32.png" sizes="32x32">
    <!-- Google fonts -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@300;400;600;700;800&family=Raleway:wght@700&display=swap" rel="stylesheet">
    <!-- CSS Reset -->
    <link rel="stylesheet" href="css/reset.css">
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/about.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <!-- Indications and Usage -->
        <div class="indications">
            <h5 class="indications__title">Indications and Usage</h5>
            <p class="indications__body copyright">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon veriﬁcation and description of clinical beneﬁt in the conﬁrmatory trial.</p>
        </div>
        <!-- Navigation -->
        <nav class="nav">
            <!-- Logo -->
            <a class="nav__logo" href="index.html">
                <img src="https://beleodaq.com/hcp/wp-content/uploads/2019/04/logonew.png" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL">
            </a>
            <!-- Header Buttons -->
            <div class="nav__buttons">
                <!-- Site Buttons (redirecting to other parts of site) -->
                <ul class="site-buttons">
                    <li>
                        <a class="site-buttons__button p" href="#">
                            Important Safety Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button p"
                        href="#">
                           Prescribing Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button button--orange p" href="#">
                           Patient Site
                        </a>
                    </li>
                </ul>
                <!-- Nav Links and Dropdown Menus -->
                <ul class="navlinks">
                    <li>
                        <a class="navlinks__link p" href="ptcl.html">PTCL <br>Overview</a>
                    </li>
                    <li class="active">
                        <a class="navlinks__link--active p" href="about.html">About <br>Beleodaq</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">BELIEF <br>Trial</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="efficacy.html"><br>Efficacy</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Study design
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Baseline Characteristics
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Response Rate
                                </a>
                             </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Duration of Response
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Safety & Tolerability</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Adverse Reactions
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Tolerability
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Dosing & Administration</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dosing Schedule
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dose Modifications
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Access & Resources</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    STAR
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Resources
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Contact <br>Us</a>
                    </li>
                </ul>
            </div>
        </nav>
    </header>
    <!-- Main -->
    <main>
        <h2 class="primary">BELEODAQ Is a Pan-HDAC Inhibitor FDA Approved for R/R PTCL</h2>
        <h3 class="secondary-variant">Although the exact mechanism of action (MOA) of HDAC inhibitors is still being studied, BELEODAQ is believed to work as follows:</h3>

        <ol>
            <li>
                <h4 class="light">
                    HDACs catalyze the removal of acetyl groups from the lysine residues of histones, which promotes a closed chromatin structure. HDACs also remove acetyl groups from some nonhistone proteins<sup>1,2</sup>
                </h4>
            </li>
            <li>
                <h4 class="light">
                    In vitro, BELEODAQ inhibits the enzymatic activity of HDACs at nanomolar concentrations (&lt;250 nM). This causes accumulation of acetylated histones and nonhistone proteins, which can promote an open chromatin structure<sup>2,3</sup>
                </h4>
            </li>
            <li>
                <h4 class="light">
                    BELEODAQ induces cell-cycle arrest and/or apoptosis of some transformed cells. BELEODAQ shows preferential cytotoxicity toward tumor cells compared to normal cells<sup>3</sup>
                </h4>
            </li>
        </ol>

        <img src="assets/svg/about-graphic.svg" alt="Although the exact mechanism of action (MOA) of HDAC inhibitors is still being studied, BELEODAQ is believed to work as follows" />
        
        <p class="light">1. Li W, et al. Int J Mol Sci. 2019;20. doi:10.3390/ijms20071616. 2. Milazzo G, et al. Genes. 2020;11. doi:10.3390/genes11050556. 3. BELEODAQ®[Prescribing Information], Acrotech Biopharma, LLC; January 2020.</p>
        <div class="button-group">
            <a href="ptcl2.html" class="button secondary">&larr; PTCL Overview</a>
            <a href="about.html" class="button">Belief Trial&rarr;</a>
        </div>
    </main>
    <!-- ISI -->
    <footer>
        <section class="isi">
            <div>
                <h5 class="isi__header">Select Important Safety Information</h5>
                <p class="isi__body copyright"><span class="isi__body--bold ">Warnings and Precautions</span>
                    BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary.</p>
            </div>
            <a class="isi__button p" href="#">
                See More <span>&uarr;</span>
            </a>
        </section>
    </footer>
    <!-- Vanilla JS -->
    <script src="js/app.js"></script>
</body>
</html>